Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryHighmark Pennsylvania Ajovy Prior Auth Coverage | …
    Ask Trek AI about this page
    CurrentHighmark PennsylvaniaPolicy N/A

    Medication prior authorization form for Ajovy (migraine prophylaxis)

    Customize your policy alerts

    Sign up for all Highmark Pennsylvania policy alerts

    Know when Highmark Pennsylvania releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is a medication prior authorization (PA) form used by Highmark Pennsylvania to collect member, provider, clinical, and treatment information to request coverage for Ajovy for migraine prevention. It affects prescribing physicians and members seeking authorization for the medication.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicyMedication prior authorization form for Ajovy (migraine prophylaxis)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and fax the Ajovy prior authorization form with required clinical documentation to 1-866-240-8123.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8number of numbered clinical questions/sections on the form
    30/90day supply options provided
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    migraine frequency categories captured

    Coverage Criteria for Ajovy (migraine prevention)

    Form completion and clinical response requirements

    Covered when ALL of the following required form fields and clinical response criteria are documented:

    Complete required form fields: Provider must complete member information, provider information, medication information (name, strength, quantity, day supply, directions) and the clinical information section of the Ajovy prior authorization form.

    See form instructions and medication information fields

    Diagnosis and baseline migraine frequency: Select and document diagnosis as Episodic Migraine Prophylaxis (4-14 headache days per month) OR Chronic Migraine Prophylaxis (15 or more headache days per month, of which 8 or more are migraine days). Provide the member's average migraine days per month prior to starting Ajovy and record the member's weight (with units).episodic 4-14 days; chronic >=15 days with >=8 migraine days

    chunk 3

    Assessment for secondary causes: Document whether headaches are caused by medication rebound/overutilization or lifestyle factors (Yes/No).

    chunk 3

    Prior preventive therapy trials: Indicate therapeutic failure or intolerance to one or more listed preventive therapies (anti-epileptic drugs, beta-blockers, calcium-channel blockers, SNRIs, tricyclic antidepressants, Botox, alpha-agonists, ACE inhibitors/ARBs, or other specified agents).documented failure or intolerance

    chunk 4

    Concomitant CGRP agent assessment: If Ajovy will be used concurrently with another CGRP agent for acute use (for example, Nurtec ODT, Ubrelvy), document Yes/No and, if yes, attest that the benefits of concurrent therapy outweigh the risks.attestation required if concurrent use

    chunk 4

    Response criteria for continuation of therapy

    • 50% responder threshold: At least a 50% reduction in the number of migraine days per month compared to start of therapy.>=50% reduction

      chunk 4

    • Episodic migraine response: For members with episodic migraine, a reduction of at least 4 monthly migraine days since start of therapy.>=4 fewer monthly migraine days

      chunk 4

    • Chronic migraine response: For members with chronic migraine, a reduction of at least 5 monthly migraine days since start of therapy.>=5 fewer monthly migraine days

      chunk 5

    Attestation and additional information: Provide any additional pertinent clinical information and certify that the information is true, accurate, and complete; note that payment is subject to member eligibility and authorization does not guarantee payment.

    chunk 5

    The form asks whether the member's headaches are caused by medication rebound/overutilization or lifestyle factors. Identify and document these potential causes on the form, as they may affect the appropriateness of migraine preventive therapy with Ajovy and are required information for the clinical review.

    Episodic migraine (definition)
    DefinitionEpisodic migraine: 4–14 headache days per month.
    Form field locationListed under Clinical Information, question 1 as 'Episodic Migraine Prophylaxis (4-14 headache days per month)'.
    Use for coverage determinationSelect when baseline headache frequency is between 4 and 14 days/month prior to starting therapy.
    Chronic migraine (definition)
    DefinitionChronic migraine: 15 or more headache days per month, of which 8 or more are migraine days.
    Form field locationListed under Clinical Information, question 1 as 'Chronic Migraine Prophylaxis (15 or more headache days per month, of which 8 or more are migraine days)'.
    Use for coverage determinationSelect when baseline headache frequency is ≥15 days/month with ≥8 migraine days prior to starting therapy.

    Submission of a completed prior authorization form does not guarantee payment. Authorization does not guarantee payment, and services that are not medically indicated or that lack required clinical documentation may be denied. Ensure all required fields are complete and supporting records are included when faxing or mailing the form.

    Provider Actions and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Ajovy. The provider must complete and submit the Ajovy prior authorization form with the member, provider, medication, and clinical information to request coverage.

    • Submit a separate form for each medication
    • Form must include member diagnosis, weight, migraine frequency, and medication details (name, strength, quantity, day supply, directions)
    • Fax: 1-866-240-8123 or mail per form instructions
    Documentation Required

    Document Therapeutic Failure or Intolerance

    The form asks whether the member has experienced therapeutic failure or intolerance to listed preventive therapies. Providers must indicate ALL applicable prior trials (anti-epileptic drugs, beta-blockers, calcium-channel blockers, SNRIs, tricyclic antidepressants, Botox, alpha-agonists, ACE inhibitors/ARBs, or other).

    Background

    This form is used to request coverage for Ajovy, a calcitonin gene-related peptide (CGRP) monoclonal antibody, for migraine prevention. It captures the diagnosis category—episodic migraine (4–14 headache days/month) or chronic migraine (≥15 headache days/month with ≥8 migraine days)—and requests the member's average migraine days per month prior to starting Ajovy to establish baseline frequency. Use the form to document prior preventive therapy trials, weight, and response to therapy where applicable to support the authorization request.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicyMedication prior authorization form for Ajovy (migraine prophylaxis)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and fax the Ajovy prior authorization form with required clinical documentation to 1-866-240-8123.
    SourceLink
    On This Page
    Coverage Criteria for Ajovy (migraine prevention)Provider Actions and Submission RequirementsBackground
  1. List specific agents tried where applicable (examples provided on form: topiramate, valproic acid, propranolol, verapamil, venlafaxine, amitriptyline, etc.)
  2. Provide details of intolerance or inadequate response
  3. Denial Risk

    Risk of Delay or Denial for Incomplete/Illegible Forms

    Incomplete or illegible forms or missing required documentation (including physician address and clinical records) may delay review or lead to denial. Ensure all questions are answered and handwriting is legible (use blue or black ink or type).

    • Complete ALL information on the form
    • Prescribing physician (PCP or Specialist) should usually complete the form
    • Illegible entries or missing clinical documentation risk delay or denial
    Note

    Submission Channels and Contact Details

    Submission channels and contact details: fax the completed form and all clinical documentation to 1-866-240-8123 or mail per the form instructions. Provide the physician address on the form as it is required for physician notification.

    • Fax: 1-866-240-8123
    • Mail: follow mailing address instructions on the form
    • Include physician address for notification